These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1283575)

  • 1. Can the coronary atherosclerotic process be influenced by calcium antagonists?
    Kober G; Schneider W; Cieslinski G; Kaltenbach M
    Drugs; 1992; 44 Suppl 1():123-7. PubMed ID: 1283575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of cultured atherosclerotic cells for investigation of antiatherosclerotic effects of anipamil and other calcium antagonists.
    Orekhov AN; Tertov VV; Lyakishev AA; Ruda MYa
    J Hum Hypertens; 1991 Oct; 5(5):425-30. PubMed ID: 1770471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro models of anti-atherosclerotic effects of cardiovascular drugs.
    Orekhov AN
    Am J Cardiol; 1990 Dec; 66(21):23I-28I. PubMed ID: 2256465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nifedipine, verapamil and diltiazem on serum biochemical parameters and aortic composition of atherosclerotic chickens.
    García-Pérez B; Ayala I; Castells MT; Doménech G; Sánchez-Polo MT; García-Partida P; Valdés M
    Biomed Pharmacother; 2005; 59(1-2):1-7. PubMed ID: 15740928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
    Jost S; Rafflenbeul W; Deckers J; Wiese B; Hecker H; Nikutta P; Lippolt P; Lichtlen P
    Eur J Epidemiol; 1992 May; 8 Suppl 1():107-19. PubMed ID: 1505647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of verapamil on atherosclerosis.
    Leonetti G; Sampieri L; Bragato R; Comerio G
    Drugs; 1993; 46 Suppl 2():75-81. PubMed ID: 7512486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of cardiodepression from cardioprotection with calcium antagonists: diltiazem protects ischemic rat myocardium with a lower functional cost as compared with verapamil or nifedipine.
    Grover GJ; Sleph PG
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):331-40. PubMed ID: 2476610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planimetric and histological study of the aortae in atherosclerotic chickens treated with nifedipine, verapamil and diltiazem.
    García Pérez B; Ayala I; Castells MT; Madrid JF; Ortega MR; Ortega JV; Ballesta J; Fernández Pardo J; Valdés M
    Histol Histopathol; 2003 Oct; 18(4):1027-33. PubMed ID: 12973671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-channel blocking agents.
    Leonard RG; Talbert RL
    Clin Pharm; 1982; 1(1):17-33. PubMed ID: 6764159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.
    Magnani B; Dal Palù C; Zanchetti A
    Drugs; 1992; 44 Suppl 1():128-33. PubMed ID: 1283576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.
    Just H; Frey M
    Basic Res Cardiol; 1994; 89 Suppl 1():177-84. PubMed ID: 7945172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemodynamic evaluation of the action of calcium antagonists].
    Vincenzi M; Allegri P; Barbieri E; Cappelletti F; Carrozza A; De Lio U; Maiolino P; Morlino T; Ometto R
    Boll Soc Ital Cardiol; 1978; (1 Suppl):79-97. PubMed ID: 757682
    [No Abstract]   [Full Text] [Related]  

  • 14. International nifedipine trial on antiatherosclerotic therapy (INTACT).
    Lichtlen PR; Nellessen U; Rafflenbeul W; Jost S; Hecker H
    Cardiovasc Drugs Ther; 1987; 1(1):71-9. PubMed ID: 3154311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium antagonists fail to protect mammalian spinal neurons after physical injury.
    Shi RY; Lucas JH; Wolf A; Gross GW
    J Neurotrauma; 1989; 6(4):261-76; discussion 277-8. PubMed ID: 2614852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcium antagonists. Properties and current indications].
    Amoroso A; Lanciotti G; Mammarella A
    Recenti Prog Med; 1984 Apr; 75(4):353-60. PubMed ID: 6374795
    [No Abstract]   [Full Text] [Related]  

  • 17. [Electrophysiological effects of calcium-antagonists and their use in arrhythmia].
    Furlanello F; Disertori M; Vergara G; Molinis G; Guarnerio M; Stefenelli C
    Boll Soc Ital Cardiol; 1978; (1 Suppl):60-78. PubMed ID: 395963
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of calcium antagonists (verapamil and nifedipine) on blood levels of calcium and cyclic AMP in humans].
    Nami R; Martinelli M; Lo Monaco B; Pizzuti M; Nardi PL; D'Ascenzo G; Gennari C
    Minerva Cardioangiol; 1981 Jun; 29(6):339-50. PubMed ID: 6269022
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypotensive action of calcium antagonists as related to plasma noradrenaline and reactivity to noradrenaline.
    Schwietzer G; Distler A; Reeck S; Thiede HM; Philipp T
    J Hypertens Suppl; 1983 Dec; 1(2):102-4. PubMed ID: 6400109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?
    Schneider W; Kober G; Roebruck P; Noack H; Alle M; Cieslinski G; Reifart N; Kaltenbach M
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S17-23. PubMed ID: 2261941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.